LS CancerDiag Overview

  • Founded
  • 2013
  • Status
  • Private
  • Employees
  • 7
  • Latest Deal Type
  • Accelerator/​Inc
  • Latest Deal Amount
  • $43.5K
Latest Deal Amount
  • Investors
  • 4

LS CancerDiag General Information


Developer of a predictive cancer diagnostic technology intended to reduce cancer mortality rates. The company's technology offer functional test that can be used for diagnosis of MMR deficiency i.e. Lynch syndrome and simplifies diagnostics of Lynch syndrome by delivering predictive and accurate results with a fast, unique and cost-efficient method globally, enabling patients to save their lives through early detection of cancer.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Diagnostic Equipment
Other Industries
Primary Office
  • C/O Terkko Health Hub
  • Haartmaninkatu 4, Building 14
  • 00290 Helsinki
  • Finland
+358 040 0000000

LS CancerDiag Timeline

Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

LS CancerDiag Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Accelerator/Incubator 17-May-2020 $43.5K Completed Generating Revenue
3. Accelerator/Incubator 01-Jan-2019 Completed Startup
2. Accelerator/Incubator 01-Jan-2018 Completed Startup
1. Accelerator/Incubator 01-Jan-2016 Completed Startup
To view LS CancerDiag’s complete valuation and funding history, request access »

LS CancerDiag Executive Team (4)

Name Title Board Seat Contact Info
Minna Nyström Founder, Chairman & Chief Executive Officer
Niklas Lahti Chief Financial Officer
Minttu Kansikas Ph.D Chief Scientific Officer
Philippe Arnez Chief Business Officer
To view LS CancerDiag’s complete executive team members history, request access »

LS CancerDiag Board Members (2)

Name Representing Role Since
Hannes Lohi Self Board Member & Founder 000 0000
Minna Nyström LS CancerDiag Founder, Chairman & Chief Executive Officer 000 0000
To view LS CancerDiag’s complete board members history, request access »

LS CancerDiag Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

LS CancerDiag Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
EIT Health Accelerator/Incubator 000 0000 000000 0
Invest Horizon Government Minority 000 0000 000000 0
Life Science Accelerator Accelerator/Incubator Minority 000 0000 000000 0
StartUp Health Venture Capital Minority 000 0000 000000 0
To view LS CancerDiag’s complete investors history, request access »